As a result of this acquisition, Vitrolife owns 60% of the company, with an option to acquire a further 10% within six months.
Magnus Nilsson, CEO of Vitrolife, said: “We are very pleased with how ATS has developed over the past six months: the development of both sales and earnings has been stronger than planned.”